U.S. Markets closed

AstraZeneca PLC (AZN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
33.95+0.05 (+0.15%)
At close: 4:02PM EDT

33.95 0.01 (0.04%)
After hours: 4:02PM EDT

People also watch
GSKNVSSNYLLYBMY
Interactive chart
Previous Close33.90
Open33.83
Bid0.00 x
Ask0.00 x
Day's Range33.82 - 34.12
52 Week Range25.55 - 35.04
Volume4,377,047
Avg. Volume4,378,824
Market Cap84.31B
Beta0.67
PE Ratio (TTM)25.43
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.90 (5.60%)
Ex-Dividend Date2017-02-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
    Zacks2 hours ago

    Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

    Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

  • Reuters4 hours ago

    Severe asthma drug shows AstraZeneca promise beyond cancer

    AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Benralizumab will compete with GlaxoSmithKline's Nucala and Teva's Cinqair - two other new antibody drugs for severe asthma - but AstraZeneca believes its product's potency and convenient dosing could give it an edge. While most investor focus is on AstraZeneca's cancer research, particularly the immunotherapy drug durvalumab , the company also has a long history in respiratory therapy that it plans to build on with benralizumab.

  • Financial Times7 hours ago

    [$$] AstraZeneca sells Seloken European rights for $300m

    AstraZeneca, the Anglo-Swedish pharmaceuticals group, has sold the European commercial rights to its Seloken heart medicines in a deal worth more than $300m, as it moves to focus on new products in what ...